Clinical Trial: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07335562) titled 'A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis' on Jan. 09.

Brief Summary: The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis

Study Start Date: April 15, 2026

Study Type: INTERVENTIONAL

Condition: Systemic Sclerosis

Intervention: DRUG: BMS-986353

Specified dose on specified days

DRUG: Fludarabine

Specified dose on specified days

DRUG: Cyclophosphamide

Specified dose on specified days

DRUG...